Literature DB >> 32920821

Evaluating multiple surrogate markers with censored data.

Layla Parast1, Tianxi Cai2, Lu Tian3.   

Abstract

The utilization of surrogate markers offers the opportunity to reduce the length of required follow-up time and/or costs of a randomized trial examining the effectiveness of an intervention or treatment. There are many available methods for evaluating the utility of a single surrogate marker including both parametric and nonparametric approaches. However, as the dimension of the surrogate marker increases, a completely nonparametric procedure becomes infeasible due to the curse of dimensionality. In this paper, we define a quantity to assess the value of multiple surrogate markers in a time-to-event outcome setting and propose a robust estimation approach for censored data. We focus on surrogate markers that are measured at some landmark time, t0 , which occurs earlier than the end of the study. Our approach is based on a dimension reduction procedure with an option to incorporate weights to guard against potential misspecification of the working model, resulting in three different proposed estimators, two of which can be shown to be double robust. We examine the finite sample performance of the estimators under various scenarios using a simulation study. We illustrate the estimation and inference procedures using data from the Diabetes Prevention Program (DPP) to examine multiple potential surrogate markers for diabetes.
© 2020 The International Biometric Society.

Entities:  

Keywords:  clinical trials; double robust; inverse probability weighting; surrogate marker; survival; treatment effect

Mesh:

Substances:

Year:  2020        PMID: 32920821      PMCID: PMC8162900          DOI: 10.1111/biom.13370

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  29 in total

1.  A method to assess the proportion of treatment effect explained by a surrogate endpoint.

Authors:  Z Li; M P Meredith; M S Hoseyni
Journal:  Stat Med       Date:  2001-11-15       Impact factor: 2.373

2.  Comparing biomarkers as principal surrogate endpoints.

Authors:  Ying Huang; Peter B Gilbert
Journal:  Biometrics       Date:  2011-04-22       Impact factor: 2.571

3.  Doubly robust estimation in missing data and causal inference models.

Authors:  Heejung Bang; James M Robins
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

4.  Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.

Authors:  Anna S C Conlon; Jeremy M G Taylor; Michael R Elliott
Journal:  Biostatistics       Date:  2013-11-26       Impact factor: 5.899

5.  Statistical validation of intermediate endpoints for chronic diseases.

Authors:  L S Freedman; B I Graubard; A Schatzkin
Journal:  Stat Med       Date:  1992-01-30       Impact factor: 2.373

6.  Toward a curse of dimensionality appropriate (CODA) asymptotic theory for semi-parametric models.

Authors:  J M Robins; Y Ritov
Journal:  Stat Med       Date:  1997 Jan 15-Feb 15       Impact factor: 2.373

7.  Estimating the proportion of treatment effect explained by a surrogate marker.

Authors:  D Y Lin; T R Fleming; V De Gruttola
Journal:  Stat Med       Date:  1997-07-15       Impact factor: 2.373

8.  On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints.

Authors:  Ariel Alonso; Wim Van der Elst; Geert Molenberghs; Marc Buyse; Tomasz Burzykowski
Journal:  Biometrics       Date:  2014-10-01       Impact factor: 2.571

9.  Estimating and testing high-dimensional mediation effects in epigenetic studies.

Authors:  Haixiang Zhang; Yinan Zheng; Zhou Zhang; Tao Gao; Brian Joyce; Grace Yoon; Wei Zhang; Joel Schwartz; Allan Just; Elena Colicino; Pantel Vokonas; Lihui Zhao; Jinchi Lv; Andrea Baccarelli; Lifang Hou; Lei Liu
Journal:  Bioinformatics       Date:  2016-06-29       Impact factor: 6.937

10.  Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints.

Authors:  Erin E Gabriel; Michael C Sachs; Peter B Gilbert
Journal:  Stat Med       Date:  2014-10-28       Impact factor: 2.373

View more
  1 in total

1.  Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.

Authors:  Ruixuan Rachel Zhou; Sihai Dave Zhao; Layla Parast
Journal:  Stat Med       Date:  2022-02-21       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.